Biogen Statistics: A biopharmaceutical firm, is involved in discovering, developing, and delivering therapies for neurodegenerative and neurological diseases. It offers TECFIDERA, VUMERITY, and AVONEX for multiple sclerosis treatment, TYSABRI and FAMPYRA to treat spinal muscular atrophy, and FUMADERM to treat severe plaque psoriasis. Charles Weissmann and Heinz Schaller, Kenneth Murray, and Walter Gilbert founded the company in 1978. It is headquartered in Cambridge, MA.
Biogen Inc. is also a manufacturer of therapies in oncology and neurology. It is a biopharmaceutical industry that develops, manufactures, markets, and sells treatments in the areas of neurology, hematology, and immunology. Multiple sclerosis (MS), neuroimmunology (movement disorders), including Parkinson’s Disease, and Alzheimer’s Disease, as well as neuromuscular disorders such as amyotrophic lateral sclerosis and spinal muscular atrophy, are all some of the products that the company is developing. It also makes biosimilar to advanced biologics. Flixabi and Imraldi, Spinraza, and Tecfidera are some of the brand names used by the company. Biogen is present in Europe, Asia, and the US.
Statistics:
Top products of Biogen Based on Revenue 2019-2021
This statistic is a summary of Biogen’s top products for 2019-2021, according to revenue. Biogen Inc. is an American biotech company that specializes in drugs to treat neurological disorders, autoimmune disorders, and cancer. It is located in Massachusetts. Spinraza was the company’s top product in 2021 and generated revenue of approximately 1.9 million U.S. dollars.
Biogen’s Revenue from 2011 to 2021
This statistic shows the net income and revenue of Biogen Inc. from 2011 through 2021. Biogen Inc. is an American biotech company specializing in drugs for neurological disorders as well as autoimmune disorders. Biogen had revenues of approximately 11 billion dollars in 2021.
Biogen’s spending on Research and Development 2011-2021
This statistic shows how much Biogen Inc. spent on research and development between 2011-2021. In 2021, the company invested approximately 2.5 billion U.S. Dollars in research and development.
Biogen’s Total Staff 2015-2021
This graph shows the number of employees employed by Biogen during 2014-2021. It was calculated at year-end. Biogen, as of December 31, 2021, had roughly 9,600 employees. Biogen Inc. is an American biotech company specializing in drugs for neurological disorders and autoimmune diseases.
Biogen’s Total Costs and Expenses 2015-2021
This statistic shows the total cost and expense for Biogen from 2014 to 2021. It is in a million U.S. dollars. According to the company, in 2020, the operating costs and expenses increased from 5.75 trillion U.S. dollars in 2014 down to 8.9 billion U.S. dollars in 2020. Biogen Inc., an American biotech company, is specialized in drugs that treat neurological disorders, autoimmune conditions, and cancer.
Biogen’s Revenues by Type and Region 2021
This statistic shows Biogen’s revenues for 2021 by region and in a million U.S. dollars. According to the company’s annual report, Biogen’s product sales from U.S. clients totaled 3.8 billion U.S. Dollars in that year.
Biogen’s Product Revenues for 2016-2021, Sorted by Therapeutic Area.
Products for multiple sclerosis generated 6.1 million U.S. dollars in 2021. Biogen Inc., an American biotech company, specializing in drugs for neurological disorders, autoimmune conditions, and cancer, is based in Massachusetts.
Company’s History:
The year 1978-2000
1978
- Biogen NV was established in Geneva, Switzerland, by three venture capitalists and three scientists who were both highly experienced in the field of biology.
1979
- Charles Weissmann M.D. is a biogen scientist. He announced that he cloned biologically activated human leukocytes (alpha) interferon successfully. Schering-Plough was granted worldwide licensing by Biogen for interferon-alpha.
1980
- Walter Gilbert, Biogen founder and Ph.D. winner of the Nobel Prize in Chemistry for his DNA sequencing work.
1982
- The company opened its new facilities in Cambridge, Massachusetts — including its new headquarters.
1983
- After its Initial Public Offering (IPO), Biogen was listed on the Nasdaq stock exchange.
1985
- Silicon Valley venture capitalists teamed up with scientists to form IDEC Pharmaceuticals, San Francisco, California. IDEC Pharmaceuticals is a monoclonal antibody development and marketing company.
1986
- Biogen had established its first manufacturing facility, which was located in Cambridge.
1995
- Biogen expanded its presence in the U.S. at Research Triangle Park, which is located in North Carolina.
1996
- Biogen announced FDA approval for interferon Beta-1a to treat relapsing forms of multiple sclerosis. It was approved by the European Union one year later.
1997
- FDA approved IDEC’s Rituximab to treat certain types of B-cell Non-Hodgkin’s Lymphoma. This was the first monoclonal immunotherapy that was approved for cancers. FDA approves Rituximab to treat rheumatoid and granulomatosis polyangiitis, microscopic, chronic lymphocytic Leukemia, and granulomatosis.
1998
- U.S. President Bill Clinton awarded Biogen the National Medal of Technology each year. This is the highest award given to technological innovators in the U.S.
The year 2000-2020
2002
- Biogen opened a large-scale, 90,000.lb manufacturing facility in Research Triangle Park (North Carolina).
- The industry opened its first Community Lab in Cambridge, Massachusetts. This teaching center provided learning of science instruction and information on science careers for middle and high school students.
2004
- FDA approved Natalizumab, a monotherapy that can be used to treat MS patients. After that, the FDA approved Natalizumab (2008) as a treatment for moderate-to-severe Crohn’s disease for those who cannot tolerate existing therapies.
2005
- Biogen Idec and collaborator Elan Pharmaceuticals had voluntarily pulled Natalizumab off the market after discovering one confirmed case of the profound side effect known as progressive multifocal leukoencephalopathy. This infrequent but severe brain infection can cause death or severe disability.
2006
- Biogen Idec acquired Fumapharm AG. This European company created the technology that would allow dimethyl fumarate to be approved as a treatment for MS relapsing.
2009
- Acorda Therapeutics granted Biogen Idec a license for the commercialization of fampridine beyond the U.S. BiogenIdec received European approval in 2011 to use fampridine for improving the walkability of MS patients. The U.S. has dalfampridine as the name of the therapy.
2010
- Knopp Neurosciences signs a licensing deal with the company. It brings in dexpramipexole. This compound is being studied by the company to treat amyotrophic lateral sclerosis.
2011
- Biogen Idec concludes deals with Portola Pharmaceuticals regarding an oral therapy for autoimmune disorders and with Samsung Biologics concerning biosimilar in order to form a joint venture, now known as Samsung Bioepis.
- The European Union and Canada launch a new delivery method for interferon-alpha-1a. It is approved by the U.S. in the year following. This product provides dosing innovation to people with MS.
2012
- Biogen Idec is helping to establish an innovative research consortium that will find new strategies to treat amyotrophic lateral syndrome (ALS). It works in conjunction with National Hemophilia Foundation, the American Thrombosis and Hemostasis Network, and the Puget Sound Blood Center on an ongoing national program offering no-cost genetic testing for those who suffer from hemophilia as well as their families. Biogen Idec announced a collaboration with Isis Pharmaceuticals (which later became Ionis Pharmaceuticals) to identify new approaches to treating spinal muscular atrophy (SMA), myotonic dystrophy type 1, and neurological/neuromuscular disorders
- Biogen Idec buys Stromedix, which is a biotechnology firm with a focus on the development of new treatments for organ failure and fibrosis.
2013
- Biogen Idec had announced disappointed Phase III results for dexpramipexole that was under investigation to treat amyotrophic lateral sclerosis (ALS). The study showed that dexpramipexole doesn’t slow down the progress of ALS.
- Biogen Idec has signed new agreements of collaboration and agreements with Galapagos NV subsidiary BioFocus on an anti-autoimmune treatment for skin disease, scleroderma, as well as with Ionis Pharmaceuticals on therapies for neurological disorders.
2015
- Biogen acquired U.K.-based Convergence Pharmaceuticals, a biopharmaceutical company in the clinical stage which will add to the pipeline of candidates to treat neuropathic pain.
2016
- Biogen announced a collaboration with the University of Pennsylvania on multiple gene therapies.
2017
- The European Commission approved etanercept, the first etanercept biosimilar, and infliximab-based biosimilar to be used within the European Union.
2018
- The Biogen Foundation commits $10 million to STEM education in Cambridge and Somerville, Massachusetts.
Recent Developments:
The year 2022
- In January, Biogen agreed to sell a 50% stake to Samsung Biologics and Samsung Bioepi for US$2.3 billion.
The year 2021
- In January, Biogen and Atlanta Therapeutics entered into a strategic collaboration to develop RNAi therapeutics for neurodegenerative diseases.
- The company obtained US FDA approval in February for an intramuscular injection route for Plegridy, which is used to treat multiple sclerosis relapse.
- In January, Biogen entered into a license agreement with CEVEC Pharmaceuticals GmbH for the use of CEVEC’s proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus vectors for gene therapy applications.
- In May, Biogen and Capsigen Inc. entered into a collaboration to develop novel adeno-associated virus capsids for CNS and neuromuscular disorders.
- In May, Biogen signed a new collaboration with Envisagenics to advance RNA splicing research within central nervous system diseases.
- In May, Biogen entered into a gene therapy collaboration with Ginkgo Bioworks to develop novel gene therapy manufacturing platform to treat certain neurological and neuromuscular diseases.
- In May, Biogen, a next-generation manufacturing plant in Solothurn (Switzerland), received a Good Manufacturing Practice multiproduct license from the Swiss Agency for Therapeutic Products.
- In July, Biogen entered into a license and collaboration agreement with InnoCare Pharma Limited for Orelabrutinib, a CNS penetrant BTK inhibitor to treat people with multiple sclerosis.
- In July, Biogen and Mirimus entered into a collaboration to develop RNAi-based therapeutics for neurological disease indications.
- In July, Biogen, along with AbbVie and Pfizer, entered into a collaboration to create a browsable resource linking rare protein-coding genetic variants to human health and disease.
- Biogen and the Eisai Company, Ltd. obtained approval from the U.S. Food and Drug Administration for a new label ADUHELM injection of 100mg/ml.
- In October, Biogen announced that it had enrolled the first patient in Phase 2 clinical trials of orelabrutinib (Bruton’s tyrosine kinase) inhibitor orelabrutinib to treat multiple sclerosis in China.
